BAYRY
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- FDA accepts Bayer’s sNDA and grants Priority Review to Lynkuet (elinzanetant) for moderate to severe vasomotor symptoms associated with endocrine therapy for breast cancerSep 28, 2026
- Bayer received FDA approval for KERENDIA (finerenone) as the first new treatment in 30 years for adults with chronic kidney disease and type 1 diabetesSep 17, 2026
- FDA granted accelerated approval to Bayer's sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancerSep 9, 2026
- Bayer presented the Phase 3 REVEAL study of investigational PET radiotracer iodine-124 evuzamitide as a late-breaking presentation at ESC 2026Aug 31, 2026
- LYNKUET received expanded marketing authorization in Canada for moderate-to-severe vasomotor symptoms caused by adjuvant endocrine therapy related to breast cancerAug 18, 2026